Abstract:

Ｏｂｊｅｃｔｉｖｅ：To observe the effects and safty of argatroban and low molecular weight heparin in patients with intermittent bedside hemofiltration treatment, and assess the feasibility of argatroban as an anticoagulant.
Ｍｅｔｈｏｄｏｌｏｇｙ：From January 2014 to December 2014, one hundred and fifty four patients received routine intermittent bedside hemofiltration were selected into this study. They were randomly divided into two groups: 56 patients were taken argatroban anticoagulation as argatroban group; and 98 patients were recieved low molecular weight heparin anticoagulant therapy as a low molecular weight heparin group. The activated prothrombin time (APTT), hemoglobin (Hb), platelet count (PLT), transmembrane pressure in the filter, the filter of residual blood, the life of the filter as the anticoagulant effect observed indicators were compared between two groups of patients before treatment, for the first time after the end of the fifth course and, the risk of bleeding as outcome measures of anticoagulation security was also compared.
Ｒｅｓｕｌｔｓ：Before treatment, the levels of APTT in argatroban group were higher than that in LMWH group, while the levels of Hb, and PLT were lower than that in low molecular weight heparin group; two sets of data had significant differences (P<005). The first and fifth after the second course of treatment, the levels of APTT, Hb, and PLT level were no significant change in patients with argatroban (P>005). In patients with low molecular weight heparin, the level of Hb was no significant change (P>005), while the level of APTT was increased, and PLT was decreased significantly (P<005). After the first treatment, filters transmembrane pressure between the two groups, the residual blood filter, the filter life was no significant difference (P>005); anticoagulant during dialysis treatment, both groups of patients had no significant bleeding tendency, bleeding was no significant difference (P>005).
Ｃｏｎｃｌｕｓｉｏｎ：Argatroban as similar to low molecular weight heparin is efficiency and safety to be used in patients with intermittent bedside hemofiltration treatment.